Atara Biotherapeutics, Inc.

NASDAQ:ATRA

Biotechnology

Healthcare
$6.77 +1.96%

+$0.19 today

Market cap
$68.98M
Beta
0.11
P/E (TTM)
-14.7
EPS (TTM)
-$0.67
52W Low $3.92High $19.15

Volume 0.02M

Average 1.40M

ATRA Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

Atara Biotherapeutics, Inc.NASDAQ: ATRA

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization declines year over year

Q1 FY2026 depreciation & amortization of $29K fell 98.4% year over year, behind the -93.6% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 40.8% from the prior quarter. Over 3 fiscal years it compounded at -27.9% a year.

Context

  • Depreciation & amortization amounted to 1.8% of revenue in FY2025, down 2.2 pp from a year earlier.
  • Depreciation & amortization increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -98.4% toward the trailing-twelve-month pace of -93.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$29K-40.8% QoQ
Last fiscal yearDec 2025
$2.12M-58.1% YoY
LTMMar 2026
$350K-93.6% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-98.4%——
1 year-58.1%——
3-year CAGR-27.9%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the income statement

Latest · FY2025
2.12M USD
Year-over-year change
-58.1%
4-year CAGR
-31.0%

Depreciation & Amortization vs competitors

How ATRA compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -93.6% is the lowest of 11, against a peer median of -13.0%.
  • Depreciation & amortization amounts to 1.5% of revenue for ATRA, versus a peer median of 5.6%.
ATRA Competitors
Depreciation & Amortization for ATRA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MGNXMacroGenics, Inc.LTM Mar 2026$7.09M USD-5.1%-15.4%4.5%
STROSutro Biopharma, Inc.LTM Mar 2026$6.7M USD-8.9%-4.0%6.7%
STTKShattuck Labs, Inc.LTM Mar 2026$3.64M USD-3.9%+6.3%364.3%
CSBRChampions Oncology, Inc.LTM Jan 2026$1.45M USD-14.9%+0.3%2.5%
CLNNClene Inc.LTM Mar 2026$1.45M USD-11.2%+13.6%1079.1%
IFRXInflaRx N.V.LTM Mar 2026€392.86K EUR-17.3%-11.1%1339.4%
ATRAAtara Biotherapeutics, Inc.LTM Mar 2026$350K USD-93.6%-27.9%1.5%
OVIDOvid Therapeutics Inc.LTM Mar 2026$167K USD-73.0%-39.9%2.3%
ORMPOramed Pharmaceuticals Inc.LTM Mar 2026$121K USD-27.5%-67.8%—
CNTXContext Therapeutics Inc.LTM Mar 2026$48.3K USD+290.5%+20.6%—
COYACoya Therapeutics, Inc.LTM Mar 2026$23.33K USD-14.7%+0.0%0.3%
Peer median (excluding ATRA) —-13.0%-2.0%5.6%

Competitors are the stored peer set for ATRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue20.34M63.57M8.57M128.94M120.77M
Cost of Revenue282M269.99M8.89M21.01M21.21M
Gross Profit(261.66M)(206.42M)(313K)107.93M99.56M
Gross Margin-1286.4%-324.7%-3.7%83.7%82.4%
Research & Development282M272.53M224.79M151.48M37.45M
Selling, General & Admin78.8M68.13M50.91M39.89M26.25M
Operating Expenses78.8M74.1M275.69M191.37M63.7M
Depreciation & Amortization9.35M5.65M4.83M5.05M2.12M
EBITDA(330.75M)(222.26M)(266M)(75.75M)38.63M
EBITDA Margin-1626.1%-349.6%-3102.7%-58.7%32.0%
Operating Income(340.46M)(280.51M)(276.01M)(83.44M)35.86M
Operating Margin-1673.9%-441.2%-3219.5%-64.7%29.7%
Interest Income367K3.06M5.43M2.11M683K
Interest Expense0373K5.29M4.62M3.79M
Other Income / Expenses367K52.22M(105K)(1.98M)(3.14M)
Income Before Tax(340.1M)(228.29M)(276.11M)(85.42M)32.72M
Pre-Tax Margin-1672.1%-359.1%-3220.7%-66.2%27.1%
Income Tax Expense46K12K15K(12K)31K
Net Income(340.14M)(228.3M)(276.13M)(85.4M)32.69M
Net Margin-1672.3%-359.1%-3220.9%-66.2%27.1%
EPS (Basic)(90.78)(55.96)(65.18)(11.41)2.61
EPS (Diluted)(90.78)(55.96)(65.18)(11.41)2.57
Weighted Avg Shares3.75M4.08M4.24M7.49M12.54M
Weighted Avg Shares (Diluted)3.75M4.08M4.24M7.49M12.72M

Atara Biotherapeutics, Inc.

NASDAQ:ATRA

Intrinsic Alpha fair value

Locked

Current Price

$6.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.